1. Bass A. Side Effects – a prosecutor, a whistleblower, and a bestselling antidepressant on trial. Chapel Hill: Algonquin Books; 2008.

2. Caplan P.J. They Say You’re Crazy: how the world’s most powerful psychiatrists decide who’s normal. Jackson: Da Capo Press; 1995.

3. Angell M. ‘The illusions of psychiatry’: an exchange. New York Rev Books. 2011 Aug 18.

4. Moynihan R. Medicalization. A new deal on disease definition. BMJ. 2011; 342: d2548.

5. Harris G., Carey B., Roberts J. Psychiatrists, children and drug industry’s role. New York Times. 2007 May 10.

6. Insel T.R. Psychiatrists’ relationships with pharmaceutical companies: part of the problem or part of the solution? JAMA. 2010; 303: 1192–3.

7. Moynihan R. Is the relationship between pharma and medical education on the rocks? BMJ. 2008; 337: 484–5.

8. Watts G. More psychiatrists attack plans for DSM-5. BMJ. 2012; 344: e3357.

9. Moynihan R., Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.

10. Boseley S. Prozac, used by 40m people, does not work say scientists. The Guardian. 2008 Feb 26.

11. Brown J., O’Brien P.M.S., Marjoribanks J., et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009; 2: CD001396.

12. [Work environment and treatment modalities in Danish psychiatry]. Nordjyske Medier; 2007.

13. Total sales of medicinal products. Danish Medicines Agency. 2011.

14. IMS Health reports U.S. prescription sales grew 51. percent in 2009, to $3003. billion. IMS Health press release. 2010 April 1.

15. Kessler R.C., Demler O., Frank R.G., et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005; 352: 2515–23.

16. Spence D. The psychiatric oligarchs who medicalise normality. BMJ. 2012; 344: e3135.

17. Gross J. Checklist for camp: bug spray, sunscreen, pills. New York Times. 2006 July 16.

18. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.

19. Schwarz A. Attention disorder or not, pills to help in school. New York Times. 2012 Oct 9.

20. GFK Denmark. [Focus group about treatment of ADHD in children and adolescents]. Letter. 2011 Nov 23.

21. Whitaker R. Anatomy of an Epidemic. New York: Broadway Paperbacks; 2010.

22. Morbidity and Mortality Weekly Report. Current depression among adults – United States, 2006 and 2008. JAMA. 2010; 304: 2233–5.

23. The Patient Health Questionnaire (PHQ-9). Available online at: Available online at: www.agencymeddirectors.wa.gov/Files/depressoverview.pdf (accessed 20 October 2012).

24. Healy D. Let them eat Prozac. New York: New York University Press; 2004.

25. Frances A. Antidepressant use has gone crazy: bad news from the CDC. Psychiatric Times. 2011 Oct 28.

26. Friedman R.A. Grief, depression, and the DSM-5. N Engl J Med. 2012; 366: 1855–7.

27. Nielsen M., Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. Int J Risk Saf Med. 2011; 23: 125–32.

28. Open letter to DSM-5. Online petition. Available online at: www.ipetitions.com/petition/dsm5/.

29. Spence D. Bad medicine: bipolar II disorder. BMJ. 2011; 342: d2767.

30. Martin A., Young C., Leckman J.F., et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004; 158: 773–80.

31. Shea S.E., Gordon K., Hawkins A., et al. Pathology in the Hundred Acre Wood: a neurodevelopmental perspective on A.A. Milne. CMAJ. 2000; 163: 1557–9.

32. The creation of the Prozac myth. The Guardian. 2008 Feb 27.

33. Spence D. Bad medicine: adult attention-deficit/hyperactivity disorder. BMJ. 2011; 343: d7244.

34. Aagaard L., Hansen E.H. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat. 2011; 7: 729–44.

35. More fraud from drug giant GlaxoSmithKline companies – court documents show. Child Health Safety. 2010 Dec 1.

36. Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012.

37. Nemeroff C.B., Mayberg H.S., Krahl S.E., et al. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacol. 2006; 31: 1345–55.

38. Volpe M. Dr. Charles Nemeroff and Emory University’s culture of corruption. The Provocateur. 2009 July 10.

39. Nugent T. Profi le in courage: A beleaguered whistle-blower physician fights for patients and jobs – and wins. Opednews. 2012 Nov 1.

40. Keller M.B., McCullough J.P., Klein D.N., et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000; 342: 1462–70.

41. Angell M. Is academic medicine for sale? N Engl J Med. 2000; 342: 1516–8.

42. Larson J.C., Ensrud K.E., Reed S.D., et al. Effi cacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011; 305: 267–74.

43. Coupland C., Dhiman P., Morriss R., et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011; 343: d4551.

44. McHugh P.R., Slavney P.R. Mental illness – comprehensive evaluation or checklist? N Engl J Med. 2012; 366: 1853–5.

45. Kleinman A. Rebalancing academic psychiatry: why it needs to happen – and soon. Br J Psych. 2012; 201: 421–2.

46. Lacasse J.R., Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med. 2005; 2: e392.

47. Goldacre B. Bad Pharma. London: Fourth Estate; 2012.

48. Castrén E. Is mood chemistry? Nat Rev Neurosci. 2005; 6: 241–6.

49. Andrews P.W., Kornstein S.G., Halberstadt L.J., et al. Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol. 2011; 2: 159.

50. Medawar C., Herxheimer A., Bell A., et al. Paroxetine, Panorama and user reporting of ADRs: Consumer intelligence matters in clinical practice and post-marketing drug surveillance. Int J Risk Saf Med. 2002; 15: 161–9.

51. Nielsen M., Hansen E.H., Gøtzsche P.C. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction. 2012; 107: 900–8.

52. Medawar C., Herxheimer A.. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. Int J Risk Saf Med. 2003/2004; 16: 5–19.

53. El-Mallakh R.S., Gao Y., Jeannie Roberts R. Tardive dysphoria: the role of long term antidepressant use in inducing chronic depression. Med Hypotheses. 2011; 76: 769–73.

54. Moore T.J., Glenmullen J., Furberg C.D. Prescription drugs associated with reports of violence towards others. PLoS One. 2010; 5: e15337.

55. Healy D. Reply to D.Wilkinson – Loss of anxiety and increased aggression in a 15-year-old boy taking fluoxetine. J Psychopharmacol. 1999; 13: 421.

56. Orriols L., Delorme B., Gadegbeku B., et al. Prescription medicines and the risk of road traffic crashes: a French registry-based study. PLoS Med. 2010; 7: e1000366.

57. FDA Approved Labeling Text for NDA 21-875/NUVIGIL™ (armodafinil) Tablets. 2007 June15.

58. Thombs B.D., Arthurs E., El-Baalbaki G., et al. Risk of bias from inclusion of patients who already have diagnosis of or are undergoing treatment for depression in diagnostic accuracy studies of screening tools for depression: systematic review. BMJ. 2011; 343: d4825.

59. Gilbody S., House A., Sheldon T. Screening and case finding instruments for depression. Cochrane Database Syst Rev. 2005; 4: CD002792.

60. Lundh A. [Is there evidence for screening for depression]? Ugeskr Læger. 2008; 170: 1479.

61. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefi eld; 2008.

62. Medawar C., Hardon A. Medicines out of Control? Antidepressants and the conspiracy of goodwill. Netherlands: Aksant Academic Publishers; 2004.

63. van Marwijk H., Allick G., Wegman F., et al. Alprazolam for depression. Cochrane Database Syst Rev. 2012; 7: CD007139.

64. Montejo A., Llorca G., Izquierdo J., et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the study of psychotropic-related sexual dysfunction. J Clin Psychiatry. 2001; 62 (Suppl. 3): 10–21.

65. Pirraglia P.A., Stafford R.S., Singer D.E. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry. 2003; 5: 153–7.

66. Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New York: Bloomsbury; 2007.

67. Boseley S. They said it was safe. The Guardian. 1999 Oct 30.

68. Healy D. Pharmageddon. Berkeley: University of California Press; 2012.

69. Internal Eli Lilly memo. Bad Homburg. 1984 May 25.

70. Virapen J. Side Effects: death. College Station: Virtualbookworm.com Publishing; 2010.

71. Pringle E. Eli Lilly hides data: Zyprexa, Evista, Prozac risk. Conspiracy Planet. Available online at: www.conspiracyplanet.com/channel.cfm?channelid=55&contentid=4181&page=2 (accessed 28 June 2012).

172. Teicher M.H., Glod C., Cole J.O. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990; 147: 207–10.

173. Lenzer J. FDA to review ‘missing’ drug company documents. BMJ. 2005; 330:7.

174. Bouchy C. Internal Eli Lilly memo. 1990 Nov 13.

175. Rosenbaum J.F., Fava M., Hoog S.L., et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998; 44: 77–87.

176. Barbui C., Cipriani A., Brambilla P., et al. ‘Wish bias’ in antidepressant drug trials? J Clin Psychopharmacol. 2004; 24: 126–30.

177. European Medicines Agency (1999/2000). EMEA/CPMP/2775/99.

178. Lenzer J. Drug secrets: what the FDA isn’t telling. Slate. 2005 Sept 27.

179. Lenzer J. Secret US report surfaces on antidepressants in children. BMJ. 2004; 329: 307.

180. Jurand S.H. Lawsuits over antidepressants claim the drug is worse than the disease. American Association for Justice. 2003 Mar 1. Available online at: www.thefreelibrary.com/_/print/PrintArticle.aspx?id=99601757 (accessed 23 December 2012).

181. Barbui C., Furukawa T.A., Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ. 2008; 178: 296–305.

182. Serna M.C., Cruz I., Real J., et al. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry. 2010; 25: 206–13.

183. Ioannidis J.P.A. Ranking antidepressants. Lancet. 2009; 373: 1759–60.

184. Laughren T.P. Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). 2006 Nov 16. Available online at: www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf (accessed 22 October 2012).

185. Fournier J.C., DeRubeis R.J., Hollon S.D., et al. Antidepressant drug effects and depression severity. A patient-level meta-analysis, JAMA. 2010; 303: 47–53.

186. DeRubeis, Fournier J.C. Depression severity and effect of antidepressant medications. JAMA. 2010; 303: 1599.

187. Johnson L.A. Pfizer disputes claim against antidepressant. USA Today. 2013 Jan 31.

188. Babyak M., Blumenthal J.A., Herman S., et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med. 2000 Sep–Oct; 62:633–8.

189. Rimer J., Dwan K., Lawlor D.A., et al. Exercise for depression. Cochrane Database Syst Rev. 2012; 7: CD004366.

190. Haug T.T., Blomhoff S., Hellstrøm K., et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003; 182: 312–8.

191. GlaxoSmithKline. Wikipedia 2012; 20 June. Available online at: http://en.wikipedia.org/wiki/GlaxoSmithKline (accessed 20 June 2012).

192. Herxheimer A. Turbulence in UK medicines regulation: A stink about SSRI antidepressants that isn’t going away. Chapter 10. In: Glavanis K, O’Donovan O, editors. Power, Politics and Pharmaceuticals: drug regulation in Ireland in the global context. Cork University Press, 2008.

193. Grassley C.E. Paxil. Speech at the US Senate. 2008 June 11.

194. Riddle M.A., King R.A., Hardin M.T., et al. Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol. 1990/1991; 1: 193–8.

195. Brynner R., Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.

196. Hansen E.H., Gyldmark M. [Psychotropic drug use. Distribution and development]. København: Sundhedsstyrelsen; 1990.

197. Glass J., Lanctôt K.L., Herrmann N., et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefi ts. BMJ. 2005; 331: 1169–73.

198. de Gage S.B., Bégaud B., Bazin F., et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012; 345: e6231.

199. Nielsen M. Selective Serotonin Reuptake Inhibitors (SSRI) – sales, withdrawal reactions and how drug regulators reacted to this with benzodiazepines as comparator [PhD thesis]. Copenhagen: University of Copenhagen; 2013.

100. Fava G.A., Bernardi M., Tomba E., et al. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol. 2007; 10: 835–8.

101. Medawar C. The antidepressant web – marketing depression and making medicines work. Int J Risk Saf Med. 1997; 10: 75–126.

102. Montgomery S.A., Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol. 1993 Fall; 8: 189–95.

103. Geddes J.R., Carney S.M., Davies C., et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003; 361: 653–61.

104. House of Commons Health Committee. The Infl uence of the Pharmaceutical Industry. Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf/apr 2005 (accessed 26 April 2005).